From: Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
Dependent variable, change from baseline | IADL | PSMS | ||||
---|---|---|---|---|---|---|
Percentage of variance accounted for | R2= 0.310, p < 0.001 | R2= 0.335, p < 0.001 | ||||
Significant predictors | ß | 95% CI (ß) | p value | ß | 95% CI (ß) | p value |
Intercept | −10.922 | −15.585, –6.259 | < 0.001 | 0.419 | −2.156, 2.995 | 0.749 |
Age at first assessment, years | −0.041 | −0.070, –0.011 | 0.007 | −0.018 | −0.036, –0.001 | 0.036 |
ADL score at baselinea | 0.521 | 0.300, 0.741 | < 0.001 | −0.175 | −0.441, 0.090 | 0.196 |
MMSE score at baseline | 0.453 | 0.267, 0.640 | < 0.001 | −0.021 | −0.128, 0.086 | 0.697 |
Number of medications at baseline | ns | −0.079 | −0.134, –0.024 | 0.005 | ||
NSAIDs/Acetylsalicylic acid (no = 0, yes = 1) | ns | 0.419 | 0.133, 0.705 | 0.004 | ||
Interaction terms: | ||||||
ADL baseline scorea × MMSE baseline score | −0.016 | −0.026, –0.006 | 0.002 | 0.018 | 0.005, 0.032 | 0.008 |